Status:
TERMINATED
MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms
Lead Sponsor:
Boston Scientific Corporation
Collaborating Sponsors:
Guidant Corporation
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to compare the benefit of cardiac resynchronization therapy (CRT)-therapy in patients with a QRS-complex of 120-150 ms to patients with a QRS-complex of \> 150 ms.
Detailed Description
The objective of this study is to compare the benefit of CRT-therapy in patients with a QRS-complex of 120-150 ms to patients with a QRS-complex of \> 150 ms within 12 months. A benefit is defined as ...
Eligibility Criteria
Inclusion
- Patients with cardiac resynchronization therapy with a defibrillator (CRT-D) or cardiac resynchronization therapy pacemakers (CRT-P) system
- New York Heart Association (NYHA) III
- Ejection fraction (EF) below 35%
- Optimised medical therapy
- QRS-complex above 120 ms
Exclusion
- Patients with CRT-P and atrial fibrillation
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00180401
Start Date
June 1 2002
End Date
October 1 2007
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Klinikum der Christian Albrecht Universität / Kardiologische Abteilung
Kiel, Germany, 24105